Acquired haemophilia caused by non-haemophilic factor VIII gene variants

Annals of Hematology

Volumn 89, Issue 6, 2010, Pages 607-612

  Tiede, Andreas ^a   Eisert, Roswith ^a   Czwalinna, Andreas ^a   Miesbach, Wolfgang ^b   Scharrer, Inge ^b   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Acquired haemophilia; Autoimmunity; Factor VIII; MHC presentation; Transfusion

Indexed keywords

BLOOD CLOTTING FACTOR 8; EPITOPE; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; BLOOD CLOTTING INHIBITOR; F8 PROTEIN, HUMAN; HLA-DRB1 ANTIGEN;

ALGORITHM; ALLELE; AMINO ACID SEQUENCE; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HEMIZYGOSITY; HEMOPHILIA; HOMOZYGOSITY; HUMAN; MALE; MISSENSE MUTATION; PREDICTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE; ADULT; AGED; CASE CONTROL STUDY; CHILD; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HEMOPHILIA A; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BLOOD COAGULATION FACTOR INHIBITORS; CASE-CONTROL STUDIES; CHILD; DNA MUTATIONAL ANALYSIS; FACTOR VIII; FEMALE; GENE FREQUENCY; HEMOPHILIA A; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 77951632334     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0887-3     Document Type: Article

References (21)

1. D Green K Lechner 1981 A survey of 215 non-hemophilic patients with inhibitors to factor VIII Thromb Haemost 45 200 203 1:STN:280: DyaL38%2FhvVWlsw%3D%3D 6792737
2. D Söhngen C Specker D Bach BM Kuntz M Burk C Aul G Kobbe A Heyll KA Hollmig W Schneider 1997 Acquired factor VIII inhibitors in nonhemophilic patients Ann Hematol 74 89 93 10.1007/s002770050263 9063379 (Pubitemid 27095482)
3. P Collins N Macartney R Davies S Lees J Giddings R Majer 2004 A population based, unselected, consecutive cohort of patients with acquired haemophilia A Br J Haematol 124 86 90 10.1046/j.1365-2141.2003.04731.x 14675412 (Pubitemid 38021627)
4. A Tiede A Huth-Kuhne J Oldenburg R Grossmann U Geisen M Krause B Brand L Alberio R Klamroth M Spannagl P Knobl 2009 Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland Ann Hematol 88 365 370 10.1007/s00277-008-0665-7 1:CAS:528:DC%2BD1MXitVOltr0%3D 19083235
5. K Peerlinck MG Jacquemin J Arnout MF Hoylaerts JG Gilles R Lavend'homme KM Johnson K Freson D Scandella JM Saint-Remy J Vermylen 1999 Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A Blood 93 2267 2273 1:CAS:528:DyaK1MXit1Khtrs%3D 10090936
6. K Fijnvandraat EA Turenhout EN van den Brink JW ten Cate JA van Mourik M Peters J Voorberg 1997 The missense mutation Arg593 ->Cys is related to antibody formation in a patient with mild hemophilia A Blood 89 4371 4377 1:CAS:528:DyaK2sXjvFCmu74%3D 9192760
7. AR Thompson ME Murphy M Liu EL Saenko JF Healey P Lollar D Scandella 1997 Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia a patient with an Arg593 to Cys mutation Blood 90 1902 1910 1:CAS:528: DyaK2sXls1GhsLY%3D 9292523
8. CR Hay CA Ludlam BT Colvin FG Hill FE Preston N Wasseem R Bagnall IR Peake E Berntorp EP Mauser Bunschoten K Fijnvandraat CK Kasper G White E Santagostino 1998 Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK haemophilia centre directors organisation Thromb Haemost 79 762 766 1:CAS:528:DyaK1cXit12nsL8%3D 9569189
9. A Sharathkumar D Lillicrap VS Blanchette M Kern J Leggo AM Stain L Brooker MD Carcao 2003 Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A J Thromb Haemost 1 1228 1236 10.1046/j.1538-7836.2003.00230.x 1:CAS:528:DC%2BD2cXktFOisr4%3D 12871324
10. B Verbruggen I Novakova H Wessels J Boezeman M van den Berg E Mauser-Bunschoten 1995 The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability Thromb Haemost 73 247 251 1:CAS:528:DyaK2MXjsl2hs70%3D 7792738
11. H Rammensee J Bachmann NP Emmerich OA Bachor S Stevanovic 1999 SYFPEITHI: database for MHC ligands and peptide motifs Immunogenetics 50 213 219 10.1007/s002510050595 1:CAS:528:DyaK1MXntlalsbs%3D 10602881
12. G Kemball-Cook EGD Tuddenham AI Wacey 1998 The factor VIII structure and mutation resource site: HAMSTeRS version 4 Nucleic Acids Res 26 216 219 10.1093/nar/26.1.216 1:CAS:528:DyaK1cXovVaktw%3D%3D 9399839 (Pubitemid 28295279)
13. M Jacquemin V Vantomme C Buhot R Lavend'homme W Burny N Demotte P Chaux K Peerlinck J Vermylen B Maillere P Van Der Bruggen JM Saint-Remy 2003 CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A Blood 101 1351 1358 10.1182/blood-2002-05-1369 1:CAS:528: DC%2BD3sXht1agtbg%3D 12393451 (Pubitemid 36182506)
14. JG Gilles JM Saint-Remy 1994 Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies J Clin Invest 94 1496 1505 10.1172/JCI117489 1:CAS:528:DyaK2cXmt1yhurk%3D 7523452
15. RR Singh BH Hahn 1998 Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis Immunol Rev 164 201 208 10.1111/j.1600-065X.1998.tb01221.x 1:CAS:528:DyaK1cXmvVWgurg%3D 9795777 (Pubitemid 28438409)
16. GF Lucas SJ Pittman S Davies T Solanki K Bruggemann 1997 Post-transfusion purpura (PTP) associated with anti-HPA-1a, anti-HPA-2b and anti-HPA-3a antibodies Transfus Med 7 295 299 10.1046/j.1365-3148.1997.d01-39.x 1:STN:280:DyaK1c7ntF2itQ%3D%3D 9510928
17. BM Alving MJ Weinstein JS Finlayson JE Menitove JC Fratantoni 1995 Fibrin sealant: summary of a conference on characteristics and clinical uses Transfusion 35 783 790 10.1046/j.1537-2995.1995.35996029166.x 1:STN:280:DyaK28%2FivFWltA%3D%3D 7570942
18. H Banninger T Hardegger A Tobler A Barth P Schupbach W Reinhart B Lämmle M Furlan 1993 Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V Br J Haematol 85 528 532 1:STN:280:DyaK2c7otlOhug%3D%3D 8136275
19. J Caers A Reekmans K Jochmans S Naegels F Mana D Urbain H Reynaert 2003 Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer Endoscopy 35 542 544 10.1055/s-2003-39678 1:STN:280: DC%2BD3s3ls1OqsQ%3D%3D 12783357 (Pubitemid 36705650)
20. N Casadevall J Nataf B Viron A Kolta JJ Kiladjian P Martin-Dupont P Michaud T Papo V Ugo I Teyssandier B Varet P Mayeux 2002 Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N Engl J Med 346 469 475 10.1056/NEJMoa011931 1:CAS:528:DC%2BD38XhtFCktr8%3D 11844847 (Pubitemid 34441737)
21. SS Guest L Levitt 2003 Pure red-cell aplasia secondary to antierythropoietin antibodies N Engl J Med 349 2572 2573 10.1056/ NEJM200312253492623 1:CAS:528:DC%2BD3sXhtVWht7jI 14695426 (Pubitemid 38010092)